The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma.

Teng-Yu LeeSheng-Shun YangHan-Chung LienYen-Chun PengChun-Fang TungTeng-Yu Lee

Published in: Journal of clinical medicine (2022)

Combining TKI and ICI provides an acceptable antitumor efficacy in first-line therapy for advanced-stage HCC patients. The survival outcomes between different TKIs or ICIs display no differences.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
tyrosine kinase
chronic myeloid leukemia
patient reported outcomes
patient reported